IL273516B2 - Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation - Google Patents

Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Info

Publication number
IL273516B2
IL273516B2 IL273516A IL27351620A IL273516B2 IL 273516 B2 IL273516 B2 IL 273516B2 IL 273516 A IL273516 A IL 273516A IL 27351620 A IL27351620 A IL 27351620A IL 273516 B2 IL273516 B2 IL 273516B2
Authority
IL
Israel
Prior art keywords
cells
acid sequence
cancer
amino acid
mutated human
Prior art date
Application number
IL273516A
Other languages
English (en)
Hebrew (he)
Other versions
IL273516A (en
IL273516B1 (en
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of IL273516A publication Critical patent/IL273516A/en
Publication of IL273516B1 publication Critical patent/IL273516B1/en
Publication of IL273516B2 publication Critical patent/IL273516B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL273516A 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation IL273516B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565464P 2017-09-29 2017-09-29
PCT/US2018/051280 WO2019067242A1 (en) 2017-09-29 2018-09-17 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53

Publications (3)

Publication Number Publication Date
IL273516A IL273516A (en) 2020-05-31
IL273516B1 IL273516B1 (en) 2025-02-01
IL273516B2 true IL273516B2 (en) 2025-06-01

Family

ID=63763012

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273516A IL273516B2 (en) 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Country Status (10)

Country Link
US (1) US20200316121A1 (enExample)
EP (2) EP4495133A3 (enExample)
JP (1) JP7391015B2 (enExample)
KR (1) KR102809909B1 (enExample)
CN (1) CN111344394A (enExample)
AU (1) AU2018342245B2 (enExample)
CA (1) CA3080274A1 (enExample)
IL (1) IL273516B2 (enExample)
SG (1) SG11202002635RA (enExample)
WO (1) WO2019067242A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016123847B3 (de) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
NZ754365A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh Novel t cell receptors and immune therapy using the same
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
CA3144070A1 (en) 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN112390875B (zh) * 2019-08-16 2023-01-24 香雪生命科学技术（广东）有限公司 一种识别afp的高亲和力t细胞受体
CN115210255A (zh) * 2019-12-17 2022-10-18 约翰斯霍普金斯大学 靶向肿瘤抗原的mana抗体及其使用方法
CN115244173A (zh) 2019-12-20 2022-10-25 英研生物(英国)有限公司 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
CA3191186A1 (en) * 2020-09-04 2022-03-10 Sanghyun Kim T cell receptors recognizing r273c or y220c mutations in p53
CN112301088B (zh) * 2020-10-21 2022-12-13 杭州纽安津生物科技有限公司 一种筛选新生抗原或新生抗原编码序列的方法
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
JP2024509472A (ja) * 2021-03-08 2024-03-01 大鵬薬品工業株式会社 Ｆｇｆｒ２及び癌ドライバー遺伝子に遺伝子変化が同時発生する患者におけるがんの治療
CN117794944A (zh) * 2021-03-31 2024-03-29 约翰斯霍普金斯大学 靶向肿瘤抗原的方法和材料
WO2022236050A1 (en) * 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
AU2022377062A1 (en) * 2021-10-29 2024-05-30 David Hou T cell receptor recognizing r175h mutation in p53 and its application
KR20250008809A (ko) 2022-04-08 2025-01-15 리제너론 파마슈티칼스 인코포레이티드 다분할 수용체 및 신호전달 복합체
WO2024131372A1 (zh) * 2022-12-23 2024-06-27 上海市第一人民医院 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用
AU2024277363A1 (en) * 2023-05-25 2025-12-11 Elicio Therapeutics, Inc. Compositions containing p53 peptide amphiphiles and methods of use thereof
CN116970058B (zh) * 2023-09-22 2023-12-15 成都朗谷生物科技股份有限公司 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用
WO2025060149A1 (zh) * 2023-09-22 2025-03-27 上海市第一人民医院 一种分离的tcr及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0643726T3 (da) 1992-05-26 2000-03-20 Seed Capital Investments Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
JPH0959175A (ja) * 1995-06-12 1997-03-04 Meiji Milk Prod Co Ltd 抗腫瘍免疫活性化剤
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
GB2440736A (en) * 2006-08-10 2008-02-13 Medical Res Council Crystals of mutant p53 polypeptidtes
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2924709T3 (es) 2014-10-02 2022-10-10 Us Health Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
EP3848456A1 (en) * 2014-10-02 2021-07-14 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
US20170333480A1 (en) * 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
US11207394B2 (en) * 2014-11-26 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated KRAS T cell receptors
KR20250024096A (ko) * 2017-09-29 2025-02-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 p53을 인식하는 t 세포 수용체

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INGE MARIE SVANE ET AL,, VACCINATION WITH P53 PEPTIDE-PULSED DENDRITIC CELLS IS ASSOCIATED WITH DISEASE STABILIZATION IN PATIENTS WITH P53 EXPRESSING ADVANCED BREAST CANCER; MONITORING OF SERUM YKL-40 AND IL-6 AS RESPONSE BIOMARKERS, 7 February 2007 (2007-02-07) *
KATERINA SHAMALOV ET AL,, THE MUTATIONAL STATUS OF P53 CAN INFLUENCE ITS RECOGNITION BY HUMAN T-CELLS, 31 January 2017 (2017-01-31) *

Also Published As

Publication number Publication date
EP4495133A3 (en) 2025-04-09
AU2018342245B2 (en) 2024-06-13
US20200316121A1 (en) 2020-10-08
JP2020534839A (ja) 2020-12-03
AU2018342245A1 (en) 2020-04-16
SG11202002635RA (en) 2020-04-29
EP4495133A2 (en) 2025-01-22
CN111344394A (zh) 2020-06-26
KR102809909B1 (ko) 2025-05-22
EP3688142A1 (en) 2020-08-05
EP3688142B1 (en) 2025-04-09
IL273516A (en) 2020-05-31
IL273516B1 (en) 2025-02-01
WO2019067242A1 (en) 2019-04-04
JP7391015B2 (ja) 2023-12-04
KR20200065026A (ko) 2020-06-08
CA3080274A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
IL273516B2 (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
JP2020534839A5 (enExample)
JP2017531640A5 (enExample)
Baecher-Allan et al. Regulatory cells and human cancer
Rezaiemanesh et al. Immune cells involved in the pathogenesis of ankylosing spondylitis
Freud et al. NKp80 defines a critical step during human natural killer cell development
Lee et al. T-cell biology in aging, with a focus on lung disease
RU2019128544A (ru) Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
US12252545B2 (en) Therapeutic cell compositions and methods of manufacturing and use thereof
Bontkes et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells
CN104087592B (zh) Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途
JP2019176869A5 (enExample)
JP2016509840A5 (enExample)
CN109266618A (zh) 能够靶向肿瘤细胞的巨噬细胞及其制备方法
JP2011188872A5 (enExample)
Yazdani et al. Characteristics of innate lymphoid cells (ILCs) and their role in immunological disorders (an update)
Kayser et al. Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy
WO2011052545A1 (ja) 抗原特異的ｂ細胞集団の製造方法
Shao et al. Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes
Kerkar et al. Timing and intensity of exposure to interferon‐γ critically determines the function of monocyte‐derived dendritic cells
Michiels et al. Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA
Lin et al. Inflammatory dendritic cells restrain CD11b+ CD4+ CTLs via CD200R in human NSCLC
Kalantari et al. Generation of large numbers of highly purified dendritic cells from bone marrow progenitor cells after co-culture with syngeneic murine splenocytes
Wolf et al. Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapy
Zygmunt et al. NKT cell stimulation with α-galactosylceramide results in a block of Th17 differentiation after intranasal immunization in mice